Use of budesonide in the treatment of pulmonary sarcoidosis.
Twenty patients with active sarcoidosis (increased serum ACE activity) and progressive pulmonary disease (stages 2-3) were treated with inhaled budesonide instead of with oral glucocorticosteroids in an open clinical study. Results after an 18-month treatment are reported. A general improvement in chest roentgenograms and FVC was noted. Serum ACE activity was normalized. The results indicate that pulmonary manifestations of sarcoidosis can be treated with the inhaled steroid, budesonide. In this way the risk of systemic side effects is considerably reduced. The final place of inhaled budesonide in the treatment of sarcoidosis must be determined via placebo-controlled and comparative, double-blinded clinical studies in larger series of patients.
D000328:Adult; D000368:Aged; D019819:Budesonide; D004341:Drug Evaluation; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011282:Pregnenediones / Q000009:adverse effects / Q000627:therapeutic use*; D011859:Radiography; D012138:Respiratory Therapy; D012507:Sarcoidosis / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D014797:Vital Capacity / Q000187:drug effects
D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide; D007703:Peptidyl-Dipeptidase A